December 30, 2022
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project Gaithersburg, MD (30 December 2022) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, congratulates ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (ImmuneOnco) on receiving US FDA IND may proceed letter for IMM2520 project. About IMM2520 IMM2520[1] is a CD47×PD-L1 […]
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project Gaithersburg, MD (30 December...
As the project partner, BLA congratulates Hangzhou Sumgen Biotech on receiving IND may proceed letter for SG1906 project
As the project partner, BLA congratulates Hangzhou Sumgen Biotech on receiving IND may proceed letter for SG1906 project Gaithersburg, MD...
As the project partner, BLA Regulatory congratulates NKGen Biotech on receiving IND may proceed letter for allogeneic SNK02 project
As the project partner, BLA Regulatory congratulates NKGen Biotech on receiving IND may proceed letter for allogeneic SNK02 project ...